Positive Phase II results for PTR-01

Positive Phase II results for PTR-01

BridgeBio Pharma and Phoenix Tissue Repair reported positive results from a phase II trial of PTR-01, an intravenously-administered recombinant collagen VII protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB).

In the trial, PTR-01 was administered once per week for four weeks and then on alternate weeks for a further 14 weeks. The open-label study reported improved wound healing and, the five patients that completed the study, reported a decrease in pain

Read the press release from BridgeBio Pharma.



Cure EB
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.